Dr. John Cush RheumNow
6 years 3 months ago
Fasinumab, nerve growth factor inhibitor, studied in a phase II trial of 421 moderate-to-severe OA (knee or hip) pts x36 wks & show to be better than placebo. But FAS had more AE (17% v 10%), Jt Surgeries (7% v 1%) and destructive arthropathy in 1 FAS pt https://t.co/eHvYrByF1Z
Dr. John Cush RheumNow
6 years 3 months ago
Truth does not belong to the one who shouts the loudest. https://t.co/QZWH5oHP6u
Dr. John Cush RheumNow
6 years 3 months ago
60,596 RA Medicare patients with MBDA testing showed in those not taking biologic/JAK inhibitor Rx, the odds of adding new Rx was 9.0% (with a low MBDA), 11.8% (moderate MBDA), and 19.7% (high MBDA, p < 0.0001). Higher MBDA yields more Drug switches https://t.co/Tu7jChQi06
Dr. John Cush RheumNow
6 years 3 months ago
Global prevalence of juvenile idiopathic arthritis is ~ 2,069,246 < 16 year olds compared with a prevalence of ~ 206,931 < 16 year olds with juvenile SLE. JIA is 10 times more prevalent than lupus in children < 16yrs. https://t.co/2xvhg59c1J
Mike Putman EBRheum
6 years 3 months ago
RECOVERY RCT, dexamethasone vs usual care in COVID19
⬇️28d mortality in pts on O2 (21.5% vs 25%, NNT ~22) or IMV (29% vs 41%, NNT~8)... ?⬆️ for pts w/out O2
1. Preprint*️⃣
2. No blinding, but hard outcome & meaningful benefit
Will likely be adopted, kudos 🇬🇧 for a useful RCT! https://t.co/m5OAYMIvZy
Dr. John Cush RheumNow
6 years 3 months ago
If you treat #SLE patients, Do you get a renal biopsy before starting therapy for Lupus nephritis?
Dr. John Cush RheumNow
6 years 3 months ago
High uric acid is associated with a higher risk of kidney cancer, especially in women; Data from a UK biobank of 444 462 without cancer w/ 6.5 yrs F/U. Highest Urate quartile had increased risk of renal cancer (HR 1.45, 95%CI 1.08 to 1.93), only in women. https://t.co/APWxFkewoF
Dr. John Cush RheumNow
6 years 3 months ago
The RheumNow Podcast is Up! Lupus Mortality Declines, But… Review of SUA and cancer; IL-12/23 and SLE; TCZ and Behcets, Pregnancy SI MRI, VTE w/ Jaks; COVID; Colchicine. Watch it here> https://t.co/2V7TbaAsOp or listen on iTunes or SoundCloud https://t.co/XMps2GTgeD
Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Colchicine has been advocated as a potential anti-inflammatory intervention in patients with the coronavirus 2 infection and clinical trials have been developed to assess its effect in early COVID-2 infection. JAMA has published a randomized clinical trial showing that low dose colchicine had less clinical deterioration without significant changes in biomarkers, such as high-sensitivity cardiac troponin and C-reactive protein.
Dr. John Cush RheumNow
6 years 3 months ago
Retrospective study of 2369 patients with Kawasaki disease examined different doses of aspirin showing lower ASA doses of 20–29 mg/kg/day was as effective as 30–50 mg/kg/day in preventing coronary artery aneurysms with no change in IVIG resistance https://t.co/kJgkSSpjyw
Dr. John Cush RheumNow
6 years 3 months ago
J&J announced that is discontinuing its phase 3 trial of ustekinumab in #SLE. An interim analysis of the 516 pt LOTUS trial showed no new safety concerns. Study was halted for lack of efficacy. A subsequent LOTUS-C trial in China has been suspended. https://t.co/iN5trI0V71
Dr. John Cush RheumNow
6 years 3 months ago
Study of 1362 #RA patients given TNF inhibitors, abatacept, tocilizumab between 2011-17 finds TCZ had best survival regardless of age; ABA had lowest D/C for adverse events & disease activity improved more with TNFi. https://t.co/7RRO9M4Wf0
Multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 infection has both similarities and differences with Kawasaki disease, and requires distinct clinical management, according to draft guidance from the American College of Rheumatology (ACR).
